The deal would end litigation accusing directors of turning a blind eye to suspiciously large opioid shipments to reap billions for the firm, which was known until 2023 as
The settlement disclosed Friday in a filing in
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.